Zhuowei Liu

Sun Yat-sen University — China

Medicine · Health Sciences

32h-index4.7kcitations208works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(63), Genital Health and Disease(36), Epigenetics and DNA Methylation(25), Renal cell carcinoma treatment(24), Urological Disorders and Treatments(24)

Publications208 total

Mitochondria-located circRCP regulates redox homeostasis via stabilizing LRPPRC/SLIRP complex to promote bladder urothelial carcinoma tumorigenesis
Cancer Letters·2025
Differentiating between adrenocortical carcinoma and pheochromocytoma by a CT-based radiomics model: a multicenter retrospective study
BMC Medical Imaging·2025· 3 citedOpen Access
Final results of a phase 2 study of HDACi chidamide and PD-1 inhibitor for advanced urothelial carcinoma after platinum therapy.
Journal of Clinical Oncology·2025
Targeting VSIG4+ tissue-resident macrophages enhances T cell cytotoxicity and immunotherapy efficacy in cancer
Developmental Cell·2025· 2 cited
Robot-assisted post-chemotherapy retroperitoneal lymph node dissection for metastatic non-seminomatous germ cell tumors using two distinct surgical approaches: A tertiary care experience
Asian journal of urology·2025· 1 citedOpen Access
RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study
BMC Cancer·2025· 4 citedOpen Access
Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study)： A phase III crossover trial
European Journal of Cancer·2025· 3 cited
Efficacy and safety of modified bleomycin administration with EP chemotherapy in adult male patients with germ cell tumors: a retrospective study
Cancer Cell International·2025· 3 citedOpen Access
AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunity
Cell Reports·2025· 2 citedOpen Access
Some characterizations of <b>RP</b> <sup> <b> [ <i>d</i> ] </b> </sup> and sensitivity for abelian group actions
Dynamical Systems·2025
Impact of adjuvant intraarterial chemotherapy on survival for patients with stage IIIA-IIIB bladder urothelial carcinoma after radical cystectomy: An open-label, prospective, randomized clinical trial.
Journal of Clinical Oncology·2025
Process Development of Key Α-Hydroxyamide Intermediate Wut-8 (Multikilogram Scale) for the Synthesis of Anti-Covid-19 Drug“Leritrelvir”
SSRN Electronic Journal·2025Open Access
Process Development of Key α-Hydroxyamide Intermediate WUT-8 (Multikilogram Scale) for the Synthesis of Anti-COVID-19 Drug 'Leritrelvir'
SSRN Electronic Journal·2025Open Access
Process Development of Key Α-Hydroxyamide Intermediate Wut-8 (82.5 Kg Scale) for the Synthesis of Leritrelvir ‒ an Antiviral Drug Against Covid-19
SSRN Electronic Journal·2025Open Access
Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer
Advanced Science·2024· 13 citedOpen Access
A predictive system comprising serum microRNAs and radiomics for residual retroperitoneal masses in metastatic nonseminomatous germ cell tumors
Cell Reports Medicine·2024· 8 citedOpen Access
The prognostic value of the 8th American Joint Committee on cancer anatomic and prognostic stage groups for penile cancer: A multicenter collaboration study
Asian journal of urology·2024Open Access
Construction and implementation of a laparoscopic skill training course based on a smartphone application and virtual reality
BMC Medical Education·2024· 4 citedOpen Access
Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
Journal of Clinical Oncology·2024· 2 cited
Updated results on multiple antigens stimulating cellular therapy (MASCT-I) in metastatic urothelial carcinoma: A randomized, open-label, phase I trial.
Journal of Clinical Oncology·2024
page 1 of 11Next →

Frequent Co-authors

Fangjian Zhou(17), Hui Han(16), Kai Yao(14), Shengjie Guo(11), Zhiling Zhang(9), Zike Qin(9), Frank Yonghong Li(8), Fang-Jian Zhou(7), Dan Xie(7), Zi-Ke Qin(7), Pei Dong(7), Xiangdong Li(6), Yunlin Ye(6), Junhang Luo(5), Minhua Deng(5), Ranyi Liu(5), Fangjian Zhou(5), Tianxin Lin(5), Shaoxu Wu(4), Minghai Tang(4)